The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 222.00
Bid: 221.50
Ask: 222.50
Change: -1.00 (-0.45%)
Spread: 1.00 (0.451%)
Open: 220.00
High: 224.00
Low: 220.00
Prev. Close: 223.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Rockhopper loss widens; Synectics inks new contract

Thu, 28th Sep 2023 15:08

(Alliance News) - (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Rockhopper Exploration PLC - Salisbury, England-based oil and gas exploration company - Pretax loss in the six months ended June 30 widens to USD2.6 million from USD749,000 a year prior as administrative expenses jump 40% to GBP2.1 million. Records no revenue in the half year compared to USD523,000 a year ago due to the ceasing of production. Says "the existing portfolio continues to be evaluated for further opportunities, but revenue and cost of sales are not expected to be material in the immediate future." Looking ahead, says work continues on refining a new lower cost development and financing plan for its Sea Lion project in the Falkland Islands.

----------

PureTech Health PLC - Boston-based biotechnology company - Says founded entity Karuna Therapeutics Inc submits new drug application to the US Food & Drug Administration for KarXT for the treatment of schizophrenia. Submission is sipported by efficacy and long-term safety data from a clinical program evaluating KarXT as a treatment for schizophrenia, PureTech says. In all three placebo-controlled trials, KarXT met its primary endpoint and demonstrated a "statistically significant and clinically meaningful reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo." As a founder of Karuna, PureTech retains an equity ownership and has rights to receive milestone payments upon the achievement of certain regulatory approvals and 20% of sublicense income. PureTech Chief Innovation Officer Eric Elenko says: "KarXT, which was invented at PureTech, showcases how we invent and advance novel medicines by giving new life to drugs that have validated pharmacology but had previously not reached patients due to an issue that is now addressable with our innovations. This NDA submission is also an important milestone for patients, as it could represent the first major advance for treating schizophrenia in over 50 years if approved by the FDA."

----------

Synectics PLC - Sheffield, England-based security and surveillance systems firm - Wins new contract with West Midlands Police for the use of its open software platform, Synergy. Has collaborated with the police force since 2005. Says additional contract will see the company integrate cameras operated by the National Highways Agency throughout the West Midlands into Synergy to increase multi-agency collaboration and improve incident response times. Chief Executive Officer Paul Webb says: "The inclusion of the regional camera network from the National Highways Agency will deliver even more comprehensive situational awareness for WMP. Integrating feeds from multiple agencies is a delicate and complex process, but with our technological expertise and compliance with protocols, we are able to deliver the end-to-end solution required by WMP."

----------

SpaceandPeople PLC - Glasgow-based retail, promotional and brand experience specialist - Subsidiary POP Retail GmbH agrees to provide retail kiosks to CEMAGG Management GmbH in its shopping centres in Germany. Chief Executive Officer Nancy Cullen says: "We are delighted to have signed this agreement with CEMAGG. It helps to further expand and consolidate our network of venues in Germany, it complements our recent agreement with Multi Germany GmbH and builds on our long-standing relationship with ECE, as well as demonstrating our focus on expanding our network of clients and venues in Europe."

----------

Atome Energy PLC - Leeds, England-based green hydrogen, ammonia, and fertilizer project development in Paraguay, Iceland, and Central America - Pretax loss in the six months ended June 30 widens to USD2.9 million from USD2.5 million a year prior, driven by a 16% increase in administrative expenses to GBP2.9m. Looking ahead, says the second half of the year is an "exciting time" for project progression, and views the outlook with "significant confidence."

----------

Cornish Metals Inc - Vancouver, Canada-based mineral exploration and development firm focused on the UK and North America - Begins wet commissioning of South Crofty mine water treatment plant in Cornwall. Says MWTP is designed to treat 25,000 metres cubed per day of water pumped directly from South Crofty mine and uses high density sludge process technology to treat raw mine water and meet the company's permitted standards for discharge into the nearby Red river. Says its project delivery team is being supported by the plant designer, equipment suppliers and contractors to "fully test and commission every aspect of the process before commencing discharge to the Red river." Expects commissioning and building of the high density sludge bed to take up to three weeks, with full dewatering of the mine anticipated to commence in October. Chief Executive Officer Richard Williams says: "The commencement of wet commissioning at the South Crofty MWTP is another exciting step towards the dewatering of South Crofty mine. Our project team, supported by a small army of dedicated local contractors, has worked extremely hard over the last 12 months to take the MWTP from a conceptual flowsheet design through to a fully constructed plant."

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
21 Jun 2023 12:36

PureTech Health launches next stage of anxiety disorder drug trial

(Alliance News) - PureTech Health PLC on Wednesday said that it has started the next stage of trials for LYT-300, in order to test whether the therapy could be used to treat anxiety disorders.

Read more
7 Jun 2023 13:57

PureTech Health's Akili launches ADHD immersive treatment in US

(Alliance News) - PureTech Health PLC on Wednesday said its founded entity, Akili Inc, released an attention deficit hyperactivity disorder treatment for adult patients.

Read more
9 May 2023 11:13

PureTech's Vedanta Biosciences receives US FDA fast track designation

(Alliance News) - PureTech Health PLC on Tuesday said its founded entity, Vedanta Biosciences, has been granted fast track designation from the US Food & Drug Administration for its bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection.

Read more
4 May 2023 11:46

IN BRIEF: PureTech notes Akili's results for EndeavorRx ADHD trial

PureTech Health PLC - Boston-based biotechnology company - Says its founded entity, Akili, announced clinical trial for video game-based therapy, EndeavorRx, showed improvement in attention and quality of life for people with attention deficit hyperactivity disorder. Notes attention improved in more than 80% of adults with ADHD, while over a third of participants "no longer exhibited an attention deficit following treatment."

Read more
2 May 2023 09:34

LONDON BROKER RATINGS: HSBC raises Rightmove to 'buy' from 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
28 Apr 2023 11:13

PureTech Health yearly loss widens but remains optimistic

(Alliance News) - PureTech Health PLC on Friday said its loss widened in 2022 and revenue declined, though it hailed an "exceptional" year and expects further success in 2023.

Read more
25 Apr 2023 18:33

TRADING UPDATES: Eagle Eye signs new John Lewis deal, Neometals update

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on xxxday and not separately reported by Alliance News:

Read more
21 Apr 2023 15:51

UK earnings, trading statements calendar - next 7 days

Monday 24 April 
Brighton Pier Group PLCFull Year Results
CentralNic Group PLCTrading Statement
Checkit PLCFull Year Results
Egdon Resources PLCHalf Year Results
Keystone Law Group PLCFull Year Results
Lok'n Store Group PLCHalf Year Results
Novacyt SAFull Year Results
Tuesday 25 April 
AB Dynamics PLCHalf Year Results
Anglo American PLCTrading Statement
Associated British Foods PLCHalf Year Results
Avacta Group PLCFull Year Results
Banco Santander SAQ1 Results
Card Factory PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Corero Network Security PLCFull Year Results
Dillistone Group PLCFull Year Results
Focusrite PLCHalf Year Results
hVIVO PLCFull Year Results
IWG PLCTrading Statement
Jadestone Energy PLCFull Year Results
Loungers PLCTrading Statement
Next Fifteen Communications Group PLCFull Year Results
Northcoders Group PLCFull Year Results
Oxford BioMedica PLCFull Year Results
Quilter PLCTrading Statement
Resolute Mining LtdTrading Statement
Round Hill Music Royalty Fund LtdFull Year Results
RWS Holdings PLCTrading Statement
Travis Perkins PLCTrading Statement
WAG Payment Solutions PLCTrading Statement
Whitbread PLCFull Year Results
Wednesday 26 April 
1Spatial PLCFull Year Results
Biome Technologies PLCFull Year Results
Bunzl PLCQ1 Results
C4X Discovery Holdings PLCHalf Year Results
CRH PLCTrading Statement
Ecora Resources PLCTrading Statement
Frenkel Topping Group PLCFull Year Results
Fresnillo PLCTrading Statement
Gem Diamonds LtdTrading Statement
Glencore PLCTrading Statement
GSK PLCQ1 Results
Home REIT PLCHalf Year Results
Learning Technologies Group PLCFull Year Results
Man Group PLCTrading Statement
Pennant International Group PLCFull Year Results
RBG Holdings PLCFull Year Results
Reckitt Benckiser Group PLCTrading Statement
Sanderson Design Group PLCFull Year Results
Skillcast Group PLCFull Year Results
Smith & Nephew PLCTrading Statement
Standard Chartered PLCQ1 Results
Trifast PLCTrading Statement
Warpaint London PLCFull Year Results
Thursday 27 April 
AstraZeneca PLCTrading Statement
Barclays PLCQ1 Results
Brave Bison Group PLCFull Year Results
Capricorn Energy PLCFull Year Results
GCP Infrastructure Investments LtdTrading Statement
Howden Joinery Group PLCTrading Statement
Inchcape PLCTrading Statement
Indivior PLCQ1 Results
Inspecs Group PLCFull Year Results
J Sainsbury PLCFull Year Results
Lancashire Holdings LtdTrading Statement
Literacy Capital PLCTrading Statement
London Stock Exchange Group PLCTrading Statement
Molten Ventures PLCTrading Statement
Petrofac LtdFull Year Results
PPHE Hotel Group LtdTrading Statement
Schroders PLCTrading Statement
Spectris PLCQ1 Results
St James's Place PLCTrading Statement
Synairgen PLCFull Year Results
Taylor Wimpey PLCTrading Statement
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 28 April 
Alphawave IP Group PLCFull Year Results
Alphawave IP Group PLCTrading Statement
Argo Blockchain PLCfull Year Results
Computacenter PLCTrading Statement
Hikma Pharmaceuticals PLCTrading Statement
Industrials REIT LtdTrading Statement
James Fisher & Sons PLCFull Year Results
Kingspan Group PLCTrading Statement
LMS Capital PLCTrading Statement
Morgan Advanced Materials PLCFull Year Results
NatWest Group PLCQ1 Results
Pearson PLCTrading Statement
PureTech Health PLCFull Year Results
Record PLCTrading Statement
Renishaw PLCTrading Statement
Rotork PLCQ1 Results
Smurfit Kappa Group PLCTrading Statement
Westminster Group PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
17 Apr 2023 09:01

PureTech Health's Vedanta Biosciences boasts "promising" results

(Alliance News) - PureTech Health PLC on Monday said that its founded entity, Vedanta Biosciences, has seen positive results for its lead programme, VE303.

Read more
23 Mar 2023 12:23

LONDON MARKET MIDDAY: Bank of England lifts rates by 25 basis points

(Alliance News) - Stock prices in London were largely lower at midday on Thursday, raised UK interest rates by 25 basis points on Thursday, as widely expected, and indicated that further tightening in monetary policy may be required.

Read more
23 Mar 2023 10:11

PureTech Health says Royalty Pharma acquires Karuna Royalties

(Alliance News) - PureTech Health PLC on Thursday said Royalty Pharma PLC has acquired an interest in PureTech's royalty in Karuna Therapeutics Inc's KarXT schizophrenia treatment.

Read more
23 Mar 2023 07:24

US Royalty Pharma strikes deal with PureTech Health on KarXT royalties

(Sharecast News) - US-listed Royalty Pharma has acquired an interest in PureTech Health's royalty in Karuna Therapeutics' KarXT drug for up to $500m, with $100m in cash up front and up to $400m in additional payments contingent on the achievement of certain regulatory and commercial milestones.

Read more
20 Mar 2023 16:01

PureTech Health says Karuna KArXT trial receives positive results

(Alliance News) - PureTech Health PLC on Monday said its founded entity, Karuna Therapeutics Inc announced its phase 3 EMERGENT-3 trial of KarXT in Schizophrenia has met its primary endpoint.

Read more
28 Feb 2023 21:05

TRADING UPDATES: Eco Atlantic swings to loss; Curtis approves takeover

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
14 Feb 2023 13:27

IN BRIEF: PureTech Health to start trials for anxiety, depression drug

PureTech Health PLC - clinical-stage biotherapeutics company - Says it will advance LYT-300 for the potential treatment of anxiety disorders and post-partum depression. A placebo-controlled, phase 2a, proof-of-concept, social anxiety clinical trial is expected to begin in the first half of 2023. Results are expected by the end of the year. An open-label, phase 2a, proof-of-concept clinical trial in women with post-partum depression is expected to begin in the second half of 2023.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.